	US 12,290,513 B2
	Therapeutic methods and compositions for treating movement disorders
Bernard Mayer Ravina, Newton, MA (US); Maria G. Beconi-Barker, Bedford, MA (US); Judith Dunn, Boston, MA (US); and Mark Rogge, Sorrento, FL (US)
Assigned to VIMA THERAPEUTICS, INC., Cambridge, MA (US)
Filed by Vima Therapeutics, Inc., Cambridge, MA (US)
Filed on May 3, 2024, as Appl. No. 18/655,062.
Claims priority of provisional application 63/615,960, filed on Dec. 29, 2023.
Claims priority of provisional application 63/464,409, filed on May 5, 2023.
Prior Publication US 2024/0366583 A1, Nov. 7, 2024
Int. Cl. A61K 31/445 (2006.01); A61K 31/27 (2006.01); A61K 31/444 (2006.01)

CPC A61K 31/445 (2013.01) [A61K 31/27 (2013.01); A61K 31/444 (2013.01)]

14 Claims

1. An oral pharmaceutical composition, comprising:

(i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat a movement disorder,

(ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency of at least one side effect of the muscarinic acetylcholine receptor inhibitor, and

(iii) a pharmaceutically acceptable carrier,

wherein the muscarinic acetylcholine receptor inhibitor is (R)-trihexyphenidyl or a pharmaceutically acceptable salt thereof,

wherein the muscarinic acetylcholine receptor activator is bethanechol or a pharmaceutically acceptable salt thereof, and

wherein the pharmaceutical composition comprises the (R)-trihexyphenidyl and the bethanechol in a weight ratio of (R)-trihexyphenidyl to bethanechol of about 1:1.1 to about 1:14.